In addition to the independent research undertaken at EBRI, many collaborative research agreements and projects with outside institutes have been implemented. EBRI is very interested in establishing collaborations between the best researchers in Neurosciences, bringing together leading scientists to explore new research directions with integrated and cross-disciplinary approaches, and formulating collaborative research projects in areas of common interest.
EBRI is currently collaborating with Italian and foreign institutes and has various ongoing research projects that are financially supported by national and international organizations.
At the national level, ongoing collaborations include the Italian National Research Council (CNR), Chiesi Pharmaceutics, Scuola Normale Superiore (Pisa), University of Rome “Tor Vergata”, University of Florence, University of Catania, University of Catanzaro, and Ceinge Institute in Naples.ù
Internationally, we have established collaborations with Dresden University (German), the Edmond Lily Safra Center for Brain Sciences (Hebrew University of Jerusalem), University College London (The Wolfson Institute), Xiamen Bioway Biotech (China).
EBRI has coordinated two international projects, which have just been completed, the first funded by the European Commission (project MEMORIES - “Development, characterization and validation of new original models for Alzheimer’s Disease) and the second one co-financed by Italian Ministry of University and Research and the Massachusetts Institute of Technology.
Group leaders of EBRI are part of the European Neuroscience Initiative (ENI) network, a collaborative network made up of a selected number of prestigious neuroscience institutes in Europe.
Over the years, the Institute has received financial support from Italian Ministry of Education and Research, the Italian Ministry of Health, the Lazio Region, the Italian Institute of Technology (IIT), FILAS, European Commission, Alzheimer’s Association, Telethon Foundation.
As of 2011, EBRI also relies on the generosity of its Supporting Members to continue to move forward in brain research and advance our understanding of how the brain works.
EBRI is grateful to our Supporting Members:
Walgreens Boots Alliance is a leading international, pharmacy-led health and beauty group delivering a range of products and services to customers. Ornella Barra is currently Executive Vice President of Walgreens Boots Alliance. Working in close partnership with manufacturers and pharmacists, Walgreens Boots Alliance is committed to improving health in the local communities and helping customers and patients to look and feel their best. The company is dedicated to supporting the development of a new generation of pharmacists. Walgreens Boots Alliance is one of the 3 major contributors to the establishment of the new “Rita Levi-Montalcini Institute” at the University of Rome “Sapienza” campus.
Chiesi Farmaceutici SpA is a research-focused international Group that develops and commercializes innovative pharmaceutical solutions to improve the quality of human life. Paolo Chiesi is the Vice President of Chiesi Farmaceutici. With a high quality entrepreneurial team characterized by self-confidence and a collaborative spirit, Chiesi Farmaceutici aims to combine commitment to results with integrity, operating in a socially and environmentally responsible manner. The company is fully committed to the treatment of pulmonary diseases. In addition to improving asthma treatment, the Group is currently engaged in identifying new effective treatments for Chronic Obstructive Pulmonary Disease (COPD). The company is also involved in advanced therapies for ophthalmic and neurological diseases (including stem cells for corneal lesions, and new drugs for the treatment of Alzheimer’s disease). Chiesi Farmaceutici is one of the 3 major contributors to the establishment of the new “Rita Levi-Montalcini Institute” at the University of Rome “Sapienza” campus.
Sinobioway Group Co., Ltd., is affiliated to Peking University. Under the guidance of Aihua Pan, Sinobioway focuses on bio-industry development and bioeconomy system establishment. Sinobioway has invested in six business areas: bio-medicine, bio-agriculture, bio-energy, bio-environment, bio-service and bio-manufacturing. Sinobioway is collaborating with EBRI in the preclinical studies for the development of the NGF 61-100 for the treatment of Alzheimer’s Disease. Sinobioway is one of the 3 major contributors to the establishment of the new “Rita Levi-Montalcini Institute” at the University of Rome “Sapienza” campus.
Foto di Rita Levi Montalcini e Aihua Pan